Group 1 - ImmunityBio Inc. (NASDAQ:IBRX) is recognized as one of the 13 stocks with the highest upside potential, particularly following the initiation of a Phase 2 clinical trial for a novel combination immunotherapy targeting indolent B-cell non-Hodgkin lymphoma (iNHL) [1] - The company amended a $505 million convertible promissory note with Nant Capital LLC, allowing for the conversion of outstanding principal into shares of ImmunityBio's common stock before the note's maturity date [2] - H.C. Wainwright raised its price target for ImmunityBio from $8 to $10 while maintaining a Buy rating, noting the company's strong financial position with liquid assets exceeding short-term obligations and a current ratio of 5.77 [3] Group 2 - ImmunityBio is a clinical-stage immunotherapy company focused on developing next-generation therapies aimed at combating cancers and infectious diseases [4]